Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
62332-0730-36 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-31 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-36 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
70377-0010-22 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0010-11 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0011-22 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0011-11 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0011-23 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
70377-0012-22 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0012-11 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0012-23 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
70377-0013-22 70377-0013 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0013-11 70377-0013 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0013-23 70377-0013 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
71332-0006-12 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral June 24, 2024 In Use
71332-0006-60 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral June 24, 2024 In Use
71332-0006-90 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral June 24, 2024 In Use
31722-0362-31 31722-0362 MELPHALAN HYDROCHLORIDE MELPHALAN HYDROCHLORIDE 50.0 mg/10ml Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 23, 2024 In Use
71288-0165-53 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 10, 2023 Jan. 2, 2025 In Use
71288-0165-54 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 10, 2023 In Use
75907-0095-40 75907-0095 FLUOROURACIL FLUOROURACIL 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical April 15, 2024 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 28, 2024 In Use
82950-0001-16 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use
82950-0001-20 82950-0001 TOVORAFENIB OJEMDA 100.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF, CRAF Oral April 30, 2024 In Use

Found 10,000 results in 6 millisecondsExport these results